BARI 2D STUDY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 巴里2D试验是一项由NIH申办的、由制药商发起的多中心临床试验，其目的是确定2型糖尿病和稳定的、有记录的冠状动脉疾病患者的5年死亡率是否低于（1）初始冠状动脉血运重建策略（PTCA或CABG）联合强化药物治疗vs单独强化药物治疗，以及（2）通过胰岛素增敏方案与胰岛素供应方案实现的血糖控制（均达到<7.0%的目标HbA 1c水平）。 UAB是参与这项试验的约50个临床中心之一，该试验约有2400名患者，随访时间为5-7年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The BARI 2D trial is an NIH-sponsored, investigator-initiated, multicenter clinical trial whose objective is to determine, in patients with Type 2 diabetes mellitus and stable, documented coronary artery disease, whether 5-year mortality is lower with (1) a strategy of initial coronary revascularization (either PTCA or CABG) combined with intensive medical therapy vs intensive medical therapy alone, and (2) glycemic control achieved by an insulin sensitizaton regimen vs an insulin provision regimen (both to a target HbA1c level of <7.0%). UAB is one of about 50 clinical centers participating in this trial of about 2400 patients with follow-up of 5-7 years.